chikungunya
viru
chikv
alphaviru
transmit
mainli
femal
mosquito
speci
aed
aegypti
aed
albopictu
caus
acut
diseas
character
fever
arthralgia
case
maculopapular
rash
thibervil
et
al
infect
rare
fatal
mani
case
evolv
chronic
stage
persist
disabl
polyarthr
sever
incapacit
patient
week
even
sever
year
simon
et
al
vaccin
antivir
avail
prevent
treatment
chikv
infect
current
therapi
consist
use
analges
antipyret
antiinflammatori
agent
paracetamol
nonsteroid
antiinflammatori
drug
fig
schemat
represent
replic
cycl
chikungunya
viru
chikv
enter
cell
endocytosi
follow
bind
protein
specif
receptor
cell
surfac
within
endosom
low
ph
trigger
fusion
viral
envelop
endosom
membran
lead
releas
nucleocapsid
cytoplasm
nucleocapsid
disassembl
liber
viral
genom
translat
produc
viral
nonstructur
protein
process
nonstructur
protein
complex
form
viral
replicas
catalyz
synthesi
negativesens
rna
strand
serv
templat
synthesi
fulllength
positivesens
genom
subgenom
rna
subgenom
rna
translat
produc
structur
polyprotein
cleav
produc
individu
structur
protein
follow
assembl
viral
compon
assembl
viru
particl
releas
bud
plasma
membran
acquir
envelop
embed
viral
glycoprotein
nsaid
thibervil
et
al
aspirin
avoid
risk
bleed
potenti
risk
develop
rey
syndrom
kucharz
cebulabyrska
addit
diseasemodifi
antirheumat
drug
dmard
methotrex
sulphasalazin
could
use
sever
case
nsaid
effect
ali
ou
alla
comb
kucharz
cebulabyrska
worldwid
reemerg
chikv
weaver
forrest
develop
potent
antivir
drug
urgent
need
similar
alphavirus
entri
chikv
host
cell
facilit
interact
envelop
glycoprotein
receptor
surfac
target
cell
fig
upon
receptor
bind
viru
rapidli
intern
endocytosi
within
endosom
conform
chang
take
place
viral
envelop
glycoprotein
due
low
ph
environ
allow
fusion
envelop
glycoprotein
endosom
membran
gould
et
al
result
releas
viral
nucleocapsid
cytoplasm
disassembl
releas
viral
rna
genom
consequ
viral
genom
translat
host
cell
machineri
gener
nonstructur
polyprotein
cleav
yield
precursor
free
protein
precursor
interact
host
protein
form
initi
replic
complex
viral
replicas
synthes
negativestrand
rna
solignat
et
al
negativestrand
rna
use
templat
synthes
positivestrand
genom
rna
subgenom
rna
rna
rna
serv
mrna
synthesi
polypeptid
contain
structur
viral
protein
gould
et
al
capsid
protein
c
releas
polypeptid
autoproteas
activ
wherea
remain
polypeptid
process
endoplasm
reticulum
er
glycoprotein
form
heterodim
complex
migrat
toward
cell
membran
golgi
complex
migrat
toward
cell
surfac
cleav
cellular
furin
furinlik
proteinas
form
matur
final
nucleocapsid
complex
assembl
cytoplasm
bud
cell
membran
acquir
lipid
bilay
envelop
contain
virusencod
glycoprotein
gould
et
al
sever
step
viral
life
cycl
target
inhibit
chikv
replic
method
vitro
vivo
evalu
antivir
compound
virus
biosaf
surrog
chikv
use
identifi
antivir
molecul
order
avoid
need
facil
includ
exampl
bhk
replicon
cell
line
contain
persist
replic
chikv
replicon
pohjala
et
al
semliki
forest
viru
sfv
strain
renilla
luciferas
pohjala
et
al
howev
use
replicon
model
viral
replic
occur
involv
risk
identifi
molecul
inhibit
step
viral
life
cycl
virion
entri
releas
chikv
pseudoparticl
carri
envelop
protein
tag
luciferas
report
selvarajah
et
al
weber
et
al
heatsensit
sfv
strain
character
sever
defect
rna
replic
elev
temperatur
pohjala
et
al
could
use
evalu
effect
antivir
agent
chikv
entri
identifi
molecul
antichikv
activ
best
option
use
infecti
virus
complet
life
cycl
clinic
isol
use
antivir
screen
includ
genbank
lam
et
al
strain
genbank
khan
et
al
strain
rathor
et
al
also
laboratori
chikv
strain
ross
briolant
et
al
lam
et
al
rathor
et
al
genbank
jadav
et
al
indian
ocean
strain
strain
genbank
use
identifi
inhibitor
chikv
replic
isol
genbank
contain
mutat
protein
also
use
evalu
efficaci
antivir
compound
gupta
et
al
recombin
chikv
green
fluoresc
protein
cruz
et
al
luciferas
gene
pohjala
et
al
could
provid
easi
readout
evalu
antivir
activ
cell
viabilitycytopathogen
effect
cpe
reduct
assay
usual
employ
initi
identif
molecul
activ
chikv
bassetto
et
al
bourjot
et
al
cruz
et
al
delang
et
al
jadav
et
al
advantag
type
cellbas
assay
possibl
discoveringidentifi
new
antivir
target
also
allow
evalu
cytotox
effect
put
antivir
molecul
african
green
monkey
kidney
vero
cell
commonli
use
cell
assay
cell
type
use
screen
chikv
antivir
includ
babi
hamster
kidney
bhk
cell
human
fetal
lung
fibroblast
cell
human
embryon
kidney
cell
bronchial
epitheli
cell
human
hepatocarcinoma
cell
commonli
use
cell
line
howev
clinic
relev
chikv
diseas
human
muscl
satellit
cell
ozden
et
al
macrophag
may
relev
cell
line
suitabl
highthroughput
screen
campaign
virusinduc
cpe
score
microscop
andor
quantit
measur
colorimetr
assay
resazurin
fluoresc
reduct
assay
cruz
et
al
jadav
et
al
mtspm
method
neutral
red
dye
uptak
khan
et
al
sever
anim
model
develop
studi
pathogenesi
chikv
infect
lethal
infect
model
use
adult
immunodefici
mice
includ
fric
et
al
ifnar
mice
pal
et
al
use
assess
antivir
efficaci
small
molecul
monoclon
antibodi
chikvinduc
death
hand
immunocompet
mice
goh
et
al
lam
et
al
parashar
et
al
selvarajah
et
al
swiss
albino
mice
parashar
et
al
nonleth
infect
model
use
assess
efficaci
drug
therapi
chikvinduc
arthriti
inflamm
chloroquin
antimalari
drug
vitro
antivir
activ
number
virus
includ
hiv
sever
acut
respiratori
syndrom
sar
coronaviru
alphavirus
khan
et
al
chloroquin
inhibit
chikv
replic
vero
cell
dosedepend
manner
khan
et
al
believ
interfer
endosomemedi
chikv
intern
rais
endosom
ph
therebi
prevent
fusion
step
bernard
et
al
howev
clinic
trial
chloroquin
chikvinfect
patient
could
prove
efficaci
treatment
chikv
infect
experi
macaqu
model
also
fail
demonstr
antivir
effect
chloroquin
roqu
et
al
furthermor
recent
studi
perform
india
benefit
chloroquin
treatment
meloxicam
nsaid
observ
treatment
earli
musculoskelet
pain
arthriti
follow
acut
chikv
infect
chopra
et
al
diverg
vitro
vivo
antivir
efficaci
chloroquin
also
report
virus
influenza
paton
et
al
ebola
viru
falzarano
et
al
similarli
clinic
trial
chloroquin
influenza
viru
ebola
viru
fail
prove
effect
despit
signific
vitro
activ
virus
arbidol
broadspectrum
antivir
approv
russia
china
treatment
prophylaxi
influenza
respiratori
infect
blais
et
al
arbidol
report
inhibit
chikv
infect
cell
ec
lm
delogu
et
al
two
analogu
arbidol
recent
identifi
somewhat
higher
select
index
inhibit
vitro
replic
chikv
di
mola
et
al
arbidolresist
mutant
strain
identifi
mutat
glycin
arginin
chikv
glycoprotein
delogu
et
al
amino
acid
posit
may
involv
bind
host
receptor
compound
shown
inhibit
chikv
hemagglutin
suggest
arbidol
interfer
replic
cycl
cell
adsorpt
step
delogu
et
al
arbidol
could
also
incorpor
cellular
membran
lead
alter
membran
structur
therebi
interf
stage
viru
life
cycl
membranedepend
fusion
endosom
membran
blais
et
al
tabl
use
novel
viru
entri
assay
identif
alphaviru
entri
inhibitor
six
compound
core
includ
chlorpromazin
perphenazin
ethopropazin
thiethylperazin
thioridazin
methdilazin
identifi
possibl
alphaviru
entri
inhibitor
heatsensit
mutant
semliki
forest
viru
use
biosaf
surrog
chikv
antichikv
activ
identifi
molecul
confirm
use
recombin
strain
carri
luciferas
report
gene
chikvrluc
precis
molecular
mechan
compound
inhibit
viral
entri
yet
elucid
pohjala
et
al
epigallocatechin
gallat
egcg
major
constitu
green
tea
extract
egcg
exert
vitro
antivir
activ
sever
virus
includ
hiv
influenza
hepat
c
viru
recent
egcg
report
inhibit
vitro
chikv
replic
weber
et
al
compound
shown
inhibit
entri
therapi
surviv
chikv
infect
mice
given
h
post
infect
chikv
pseudoparticl
carri
chikv
envelop
protein
target
cell
flavaglin
famili
natur
product
shown
anticanc
cardioand
neuroprotect
properti
moreov
flavaglin
also
target
prohibitin
polier
et
al
previous
identifi
receptor
chikv
entri
mammalian
cell
wintachai
et
al
synthet
flavaglin
sulfonyl
amidin
exert
moder
antivir
effect
chikv
replic
cell
wintachai
et
al
two
compound
suggest
inhibit
entri
step
wherea
could
act
postentri
stage
coloc
chikv
glycoprotein
markedli
reduc
presenc
flavaglin
may
suggest
effect
receptor
bind
viru
wintachai
et
al
tabl
small
interf
rna
sirna
sequenc
target
chikv
gene
design
evalu
chikv
vero
cell
dash
et
al
sirna
shown
reduc
chikv
titer
sirnatransfect
cell
hour
postinfect
reduct
sustain
hour
dash
et
al
possibl
due
suscept
sirna
intracellular
degrad
rapid
replic
natur
chikv
sirna
target
combin
result
inhibit
chikv
replic
cell
treatment
chikvinfect
swiss
albino
mice
sirna
complet
inhibit
chikv
replic
administ
h
postinfect
parashar
et
al
tabl
short
hairpin
rna
shrna
chikv
shrna
result
signific
sustain
inhibit
infect
wherea
shrna
target
capsid
result
modest
inhibitori
effect
lam
et
al
pretreat
suckl
mice
lg
shrna
complet
protect
chikvinduc
diseas
surviv
day
postinfect
compar
surviv
day
pi
control
lam
et
al
resist
variant
emerg
passag
chikv
cell
stabli
express
shrna
harringtonin
cephalotaxin
alkaloid
deriv
cephalotaxu
harringtonia
report
vitro
inhibitor
chikv
replic
ec
lm
addit
homoharringtonin
stabl
analogu
harringtonin
recent
approv
fda
treatment
chronic
myeloid
leukemia
also
inhibit
chikv
replic
antichikv
activ
harringtonin
homoharringtonin
suggest
result
inhibit
host
cell
protein
translat
machineri
interestingli
harringtonin
homoharringtonin
potent
chikv
strain
carri
mutat
strain
carri
wild
type
mechan
behind
differ
yet
resolv
tabl
nonstructur
protein
chikv
multifunct
rna
helicas
rna
triphosphatas
nucleosid
triphosphatas
activ
within
ntermin
half
autoproteas
activ
process
nonstructur
viral
polyprotein
ctermin
half
fro
et
al
solignat
et
al
chikv
also
involv
shut
host
cell
mrna
transcript
translat
moreov
chikv
found
suppress
type
iii
interferonstimul
jakstat
signal
lead
inhibit
host
antivir
respons
fro
et
al
divers
function
could
target
chikv
inhibitor
especi
proteas
function
chikv
interest
proteas
virus
hiv
hcv
shown
excel
target
develop
antivir
drug
structurebas
virtual
screen
strategi
appli
select
chikv
inhibitor
base
proteas
bind
site
among
select
hit
one
lead
compound
compound
result
inhibit
chikvinduc
cpe
ec
lm
vero
cell
bassetto
et
al
compound
predict
bind
central
part
proteas
activ
site
anoth
studi
seri
arylalkyliden
deriv
evalu
vitro
antivir
activ
five
compound
shown
inhibit
chikv
cpe
reduct
assay
ec
best
compound
lm
tabl
author
propos
base
molecular
dock
studi
compound
may
target
chikv
proteas
jadav
et
al
identifi
inhibitor
target
shutoff
hostcel
transcript
machineri
phenotyp
assay
employ
assay
express
luciferas
report
gene
regul
human
transcript
factor
fo
fuse
dnabind
domain
yeast
transcript
factor
lucashourani
et
al
chikv
coexpress
fosinduc
express
luciferas
inhibit
one
compound
identifi
partial
block
activ
significantli
inhibit
vitro
replic
ec
lm
lucashourani
et
al
ribavirin
synthet
guanosin
analogu
broadspectrum
antivir
activ
ribavirin
approv
treatment
infect
respiratori
syncyti
viru
infant
turner
et
al
chronic
hepat
c
viru
infect
combin
pegyl
ifna
andor
directact
antivir
pawlotski
ribavirin
also
use
offlabel
treatment
viral
infect
lassa
viru
infect
et
al
ribavirin
shown
exert
vitro
antivir
activ
chikv
ec
lm
result
synergist
inhibitori
effect
combin
briolant
et
al
combin
ribavirin
doxycyclin
also
result
good
antivir
effect
chikv
replic
vero
cell
reduc
viral
load
inflamm
infect
icr
mice
rothan
et
al
tabl
sever
mechan
antivir
action
assign
ribavirin
paeshuys
et
al
major
mechan
ribavirin
inhibit
replic
rna
virus
flaviand
paramyxovirus
inhibit
inosin
monophosph
dehydrogenas
enzym
impdh
result
deplet
gtp
pool
leyssen
et
al
suggest
mechan
antivir
activ
ribavirin
includ
inhibit
viral
rna
cap
induct
error
catastroph
increas
mutat
rate
result
incorpor
ribavir
monophosph
viral
polymeras
paeshuys
et
al
mycophenol
acid
mpa
noncompetit
inhibitor
impdh
wide
use
immunosuppress
prevent
reject
transplant
organ
mpa
report
effect
inhibit
chikv
replic
vero
cell
mpa
even
potent
deplet
intracellular
gtppool
ribavirin
antichikv
activ
compound
ascrib
mechan
khan
et
al
uridin
analogu
broadspectrum
antivir
activ
dna
rna
virus
rada
also
inhibit
vitro
chikv
replic
vero
cell
ec
lm
briolant
et
al
compound
competit
inhibitor
orotidin
monophosph
decarboxylas
enzym
deplet
intracellular
utppool
explain
activ
rapidli
replic
virus
chikv
rada
tabl
favipiravir
broadspectrum
antivir
agent
recent
approv
japan
treatment
influenza
viru
infect
interestingli
exert
antivir
activ
sever
rna
virus
includ
rift
valley
fever
viru
carolin
et
al
scharton
et
al
arenavirus
mendenhal
et
al
hantavirus
safronetz
et
al
cell
cultur
anim
model
also
shown
endow
vitro
vivo
antivir
activ
ebola
viru
oestereich
et
al
smither
et
al
clinic
trial
current
ongo
western
africa
evalu
efficaci
patient
et
al
convert
intracellularli
ribofuranosyl
triphosph
form
competit
inhibit
incorpor
atp
gtp
viral
rnadepend
rna
polymeras
rdrp
precis
molecular
mechan
antivir
activ
total
elucid
yet
propos
mechan
action
chain
termin
nascent
viral
rna
strand
andor
ii
induct
lethal
mutagenesi
viral
genom
defluorin
analogu
inhibit
replic
differ
laboratori
strain
clinic
isol
chikv
vero
cell
includ
strain
isol
recent
outbreak
caribbean
region
addit
treatment
infect
mice
oral
dose
mgkgday
protect
mice
sever
neurolog
diseas
reduc
mortal
rate
effect
observ
specif
infect
chikv
calcul
ratio
infecti
viru
yield
genom
copi
number
suggest
error
catastroph
underli
inhibitori
effect
lowlevel
chikv
variant
select
carri
mutat
motif
rnadepend
rna
polymeras
mutat
shown
respons
phenotyp
resist
interestingli
lysin
residu
highli
conserv
polymeras
ssrna
virus
may
provid
explan
broadspectrum
antivir
activ
tabl
two
mab
isol
patient
chikv
infect
histori
found
target
viral
envelop
glycoprotein
warter
et
al
show
specif
neutral
differ
strain
chikv
plaqu
reduct
assay
warter
et
al
mab
also
protect
infect
mice
given
prophylact
fric
et
al
postexposur
administr
protect
infect
mice
result
delay
mortal
ten
day
fric
et
al
anoth
monoclon
antibodi
mab
also
isol
patient
recov
chikv
infect
epitop
mab
identifi
acidsensit
region
chikv
glycoprotein
selvarajah
et
al
mab
neutral
chikv
pseudovirion
replicationcompet
virus
vitro
complet
protect
chikv
infect
mice
arthriti
viremia
given
one
day
infect
moreov
treatment
mab
result
surviv
chikv
infect
mice
given
h
post
infect
selvarajah
et
al
tabl
screen
assay
panel
murin
mab
chikv
four
mab
result
complet
protect
infect
ifnar
mice
chikvinduc
mortal
administ
prophylact
pal
et
al
moreov
therapeut
administr
singl
dose
combin
two
mab
protect
infect
mice
mortal
administ
hour
infect
pal
et
al
epitop
mab
local
glycoprotein
effect
mab
human
show
similar
neutral
efficaci
compar
murin
mab
pal
et
al
anoth
studi
number
mab
target
chikv
glycoprotein
gener
mice
evalu
chikvneutr
activ
goh
et
al
three
mab
show
effici
neutral
chikv
vero
cell
addit
passiv
immun
mice
mab
protect
chikvinduc
arthriti
viremia
goh
et
al
anoth
murin
mab
specif
chikv
glycoprotein
isol
mous
immun
chikv
cellbas
assay
mab
inhibit
bud
releas
chikv
infect
cell
effect
viru
entri
intracellular
replic
masrinoul
et
al
cellular
furin
involv
process
viral
glycoprotein
produc
matur
virion
decanoylrvkr
chloromethyl
keton
decrvkrcmk
irrevers
furin
inhibitor
inhibit
chikv
infect
human
muscl
satellit
cell
ozden
et
al
inhibit
furin
decrvkrcmk
result
format
immatur
viral
particl
reduc
viral
spread
furthermor
combin
decrvkrcmk
chloroquin
result
addit
antivir
effect
chikv
almost
total
suppress
viru
spread
yield
pretreat
cell
decrvkrcmk
inhibit
viral
entri
ozden
et
al
protein
kinas
c
pkc
famili
serinethreonin
kinas
regul
mani
cellular
function
cell
cycl
control
prolifer
differenti
metastasi
apoptosi
prostratin
tpa
tiglian
diterpenoid
basic
phorbol
carbon
skeleton
bourjot
et
al
structur
similar
diacylglycerol
tpa
prostratin
act
potent
activ
pkc
prostratin
tpa
previous
report
exert
antivir
activ
hiv
mckernan
et
al
inhibit
chikv
replic
vero
cell
bourjot
et
al
tabl
role
pkc
chikv
life
cycl
clear
yet
screen
kinas
inhibitor
librari
vitro
chikv
infect
result
identif
six
compound
one
benzofuran
core
scaffold
one
pyrrolopyridin
scaffold
one
thiazolcarboxamid
scaffold
reduc
number
apoptot
bleb
infect
cell
result
moder
reduct
infecti
viru
yield
propos
compound
interfer
chikvinduc
cpe
format
inhibit
kinas
involv
apoptosi
cruz
et
al
tabl
heat
shock
protein
highli
abund
molecular
chaperon
involv
mani
cellular
process
signal
pathway
interact
client
protein
two
main
isoform
stressinduc
constitut
express
report
play
key
role
replic
mani
virus
hepat
c
viru
human
cytomegaloviru
influenza
viru
inhibitor
inhibit
vitro
chikv
replic
dosedepend
manner
infect
cell
rathor
et
al
treatment
infect
mice
dose
mgkg
twice
day
result
signific
reduct
serum
viral
titer
h
postinfect
treat
mice
show
swell
inflamm
cours
infect
use
coimmunoprecipit
mass
spectrometri
propos
interact
chikv
sirna
knockdown
subunit
result
greater
inhibit
chikv
replic
knockdown
subunit
also
suggest
may
play
import
role
stabil
chikv
format
chikv
replic
complex
rathor
et
al
studi
need
understand
role
life
cycl
chikv
tabl
treatment
ifna
result
signific
inhibit
vitro
replic
chikv
briolant
et
al
strain
carri
mutat
prove
sensit
antivir
activ
recombin
ifna
strain
carri
wildtyp
genotyp
bordi
et
al
polyinosin
acid
polycytidyl
acid
poli
c
synthet
analogu
dsrna
act
potent
induc
ifn
poli
c
report
inhibit
chikvinduc
cpe
human
bronchial
epitheli
cell
significantli
reduc
viru
titer
infect
cell
antichikv
activ
poli
c
may
attribut
upregul
result
stimul
ifna
ifnb
antivir
gene
oa
mxa
tabl
rigi
retino
acidinduc
gene
member
rigi
like
receptor
famili
recogn
viral
dsrna
result
tabl
antivir
chikungunya
viru
unidentifi
target
mechan
action
activ
multipl
antivir
factor
inhibit
viral
infect
rigi
also
induc
synthes
dsrna
molecul
bear
expos
triphosph
end
ppp
hornung
et
al
pichlmair
et
al
interestingli
stimul
rigi
cell
optim
triphosphoryl
rna
molecul
protect
cell
chikv
infect
reduc
viru
titer
olagni
et
al
antivir
respons
trigger
ppprna
independ
type
ifn
respons
major
advantag
boost
innat
immun
respons
rigi
agonist
low
possibl
resist
develop
broad
antivir
spectrum
tabl
inhibitor
unidentifi
target
trigocherrierin
trigocherrierin
new
daphnan
diterpenoid
orthoest
isol
ethanol
extract
trigonostemon
cherrieri
leav
bourjot
et
al
trigocherrierin
report
inhibit
vitro
replic
chikv
ec
lm
yet
unknown
mechan
debromoaplysiatoxin
isol
first
time
marin
cyanobacterium
trichodesmium
erythraeum
report
inhibit
vitro
replic
chikv
gupta
et
al
suggest
compound
might
block
postentri
step
chikv
replic
cycl
tabl
four
natur
apigenin
chrysin
naringenin
silybin
report
inhibitor
chikv
use
replicon
cell
line
infecti
virusbas
assay
pohjala
et
al
tabl
molecular
target
still
unknown
new
class
compound
triazolo
one
report
inhibit
vitro
chikv
replic
valu
low
micromolar
rang
select
indic
gigant
et
al
interestingli
compound
show
specif
antichikv
activ
littl
antivir
activ
member
togavirida
famili
gigant
et
al
mechanist
studi
current
ongo
tabl
number
uracilcoumarinaren
conjug
synthes
evalu
antivir
activ
chikv
replic
vero
cell
hwu
et
al
five
conjug
elicit
signific
inhibit
vitro
chikv
replic
low
toxic
hwu
et
al
structureact
relationship
studi
reveal
compound
scaffold
potent
seri
hwu
et
al
tabl
reemerg
chikv
togeth
sometim
sever
complic
associ
acut
chikungunya
fever
underlin
need
potent
antivir
variou
class
activ
compound
report
target
viral
host
factor
howev
vivo
efficaci
yet
evalu
anim
model
molecul
mechan
viral
replic
inhibit
demonstr
hand
compound
although
report
inhibitor
rel
weak
modest
vitro
antichikv
activ
may
use
start
point
develop
potent
specif
inhibitor
chikvalphaviru
replic
report
chikv
inhibitor
favipiravir
ribavirin
ifna
arbidol
approv
treat
patient
viral
infect
molecul
alreadi
intens
studi
patient
evalu
chikvinfect
patient
may
possibl
fasttrack
perform
control
clinic
trial
could
probabl
facilit
current
epidem
south
america
million
peopl
infect
urban
area
viru
becom
endem
becom
difficult
perform
clinic
trial
sporad
infect
approv
antivir
chikv
promis
compound
could
evalu
patient
comparison
placebo
set
first
explos
year
epidem
thu
possibl
detect
antivir
efficaci
absenc
rel
quickli
context
antichikv
activ
broadspectrum
antivir
favipiravir
may
particularli
interest
approv
treat
influenza
viru
infect
japan
drug
evalu
treatment
ebola
viru
infect
western
africa
howev
given
grow
number
patient
suffer
chikv
infect
may
justifi
develop
specif
chikv
drug
ideal
inhibitor
exert
panalphaviru
activ
exampl
use
treatment
infect
ross
river
viru
equin
enceph
virus
nowaday
highli
potent
drug
avail
treatment
limit
number
virus
hiv
herpesvirus
hepat
b
c
viru
invest
suffici
time
effort
also
possibl
develop
safe
potent
drug
treatment
andor
prophylaxi
alphaviru
infect
